A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Rituximab for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Sponsor: NIAID, DAIT, NIH
Enrolling: Male and Female Patients
Study Length: 1 Years
Clinic Visits: 9
IRB Number: AAAO0100
U.S. Govt. ID: NCT01086540
Contact: Rachel Broderick: 1-212-342-2713 / rb3173@cumc.columbia.edu
Additional Study Information: This study involves two infusions of either rituximab or placebo, two right heart catheterizations (6 months apart), and a variety of other clinical study procedures and exams.
This study is closed
Investigator
Elana Bernstein, MD
Do You Qualify?
Do you have systemic sclerosis (either limited or diffuse)? Yes No
Have you been diagnosed with pulmonary arterial hypertension in the last 5 years? Yes No
Are you taking medications for your pulmonary hypertension? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Rachel Broderick
rb3173@cumc.columbia.edu
1-212-342-2713
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE